Survival prolonged with breast cancer vaccine

Abstract

Biomira researchers plan to move to phase III trials with their therapeutic cancer vaccine ‘Theratope’ next year, following the promising results of a recent phase II study involving patients with breast cancer. The ‘Theratope’ vaccine, which is a form of active specific immunotherapy (ASI), led to a 3-fold increase in the duration of survival in patients with breast cancer, compared with that seen in a retrospective control group. A preliminary view of the results was presented to delegates at IBC USA’s 2nd Annual Conference on ‘Immunotherapeutic Strategies for Cancer’ [ San Diego, US; November 1996 ].